Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents

Yi Bin Chen, Philip L. McCarthy, Theresa Hahn, Sarah A Holstein, Masumi Ueda, Nicolaus Kröger, Michael Bishop, Marcos de Lima

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Relapse is a major cause of treatment failure after stem cell transplantation. Novel agents given as maintenance or preemptive post transplant were discussed at the 3 rd International Workshop on Biology, Prevention, and Treatment of Relapse after Stem Cell Transplantation in Hamburg/Germany in November 2016 under the auspices of EBMT and ASBMT. Maintenance therapy is started after SCT without detectable disease, while preemptive therapy is triggered by the detection of minimal residual disease (MRD). The maintenance approach treats all patients, and overtreats a significant amount. Maintenance therapy requires an agent without significant off-target toxicity. The preemptive approach only initiates therapy upon detection of MRD, while sparing further therapy to those who remain in remission. Preemptive strategies require sensitive and clinically reliable assays to detect MRD. Here current development of tyrosine kinase inhibitors (TKIs) immunomodulating drugs (IMiDs), deacetylase inhibitors, and hypomethylating agents were reviewed.

Original languageEnglish (US)
Pages (from-to)497-507
Number of pages11
JournalBone marrow transplantation
Volume54
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Hematopoietic Stem Cell Transplantation
Protein-Tyrosine Kinases
Recurrence
Residual Neoplasm
Pharmaceutical Preparations
Stem Cell Transplantation
Therapeutics
Maintenance
Secondary Prevention
Treatment Failure
Germany
Transplants
Education

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. / Chen, Yi Bin; McCarthy, Philip L.; Hahn, Theresa; Holstein, Sarah A; Ueda, Masumi; Kröger, Nicolaus; Bishop, Michael; de Lima, Marcos.

In: Bone marrow transplantation, Vol. 54, No. 4, 01.04.2019, p. 497-507.

Research output: Contribution to journalReview article

Chen, Yi Bin ; McCarthy, Philip L. ; Hahn, Theresa ; Holstein, Sarah A ; Ueda, Masumi ; Kröger, Nicolaus ; Bishop, Michael ; de Lima, Marcos. / Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. In: Bone marrow transplantation. 2019 ; Vol. 54, No. 4. pp. 497-507.
@article{79f67190de29455fa5b96e9198621e1c,
title = "Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents",
abstract = "Relapse is a major cause of treatment failure after stem cell transplantation. Novel agents given as maintenance or preemptive post transplant were discussed at the 3 rd International Workshop on Biology, Prevention, and Treatment of Relapse after Stem Cell Transplantation in Hamburg/Germany in November 2016 under the auspices of EBMT and ASBMT. Maintenance therapy is started after SCT without detectable disease, while preemptive therapy is triggered by the detection of minimal residual disease (MRD). The maintenance approach treats all patients, and overtreats a significant amount. Maintenance therapy requires an agent without significant off-target toxicity. The preemptive approach only initiates therapy upon detection of MRD, while sparing further therapy to those who remain in remission. Preemptive strategies require sensitive and clinically reliable assays to detect MRD. Here current development of tyrosine kinase inhibitors (TKIs) immunomodulating drugs (IMiDs), deacetylase inhibitors, and hypomethylating agents were reviewed.",
author = "Chen, {Yi Bin} and McCarthy, {Philip L.} and Theresa Hahn and Holstein, {Sarah A} and Masumi Ueda and Nicolaus Kr{\"o}ger and Michael Bishop and {de Lima}, Marcos",
year = "2019",
month = "4",
day = "1",
doi = "10.1038/s41409-018-0269-3",
language = "English (US)",
volume = "54",
pages = "497--507",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents

AU - Chen, Yi Bin

AU - McCarthy, Philip L.

AU - Hahn, Theresa

AU - Holstein, Sarah A

AU - Ueda, Masumi

AU - Kröger, Nicolaus

AU - Bishop, Michael

AU - de Lima, Marcos

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Relapse is a major cause of treatment failure after stem cell transplantation. Novel agents given as maintenance or preemptive post transplant were discussed at the 3 rd International Workshop on Biology, Prevention, and Treatment of Relapse after Stem Cell Transplantation in Hamburg/Germany in November 2016 under the auspices of EBMT and ASBMT. Maintenance therapy is started after SCT without detectable disease, while preemptive therapy is triggered by the detection of minimal residual disease (MRD). The maintenance approach treats all patients, and overtreats a significant amount. Maintenance therapy requires an agent without significant off-target toxicity. The preemptive approach only initiates therapy upon detection of MRD, while sparing further therapy to those who remain in remission. Preemptive strategies require sensitive and clinically reliable assays to detect MRD. Here current development of tyrosine kinase inhibitors (TKIs) immunomodulating drugs (IMiDs), deacetylase inhibitors, and hypomethylating agents were reviewed.

AB - Relapse is a major cause of treatment failure after stem cell transplantation. Novel agents given as maintenance or preemptive post transplant were discussed at the 3 rd International Workshop on Biology, Prevention, and Treatment of Relapse after Stem Cell Transplantation in Hamburg/Germany in November 2016 under the auspices of EBMT and ASBMT. Maintenance therapy is started after SCT without detectable disease, while preemptive therapy is triggered by the detection of minimal residual disease (MRD). The maintenance approach treats all patients, and overtreats a significant amount. Maintenance therapy requires an agent without significant off-target toxicity. The preemptive approach only initiates therapy upon detection of MRD, while sparing further therapy to those who remain in remission. Preemptive strategies require sensitive and clinically reliable assays to detect MRD. Here current development of tyrosine kinase inhibitors (TKIs) immunomodulating drugs (IMiDs), deacetylase inhibitors, and hypomethylating agents were reviewed.

UR - http://www.scopus.com/inward/record.url?scp=85050373909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050373909&partnerID=8YFLogxK

U2 - 10.1038/s41409-018-0269-3

DO - 10.1038/s41409-018-0269-3

M3 - Review article

VL - 54

SP - 497

EP - 507

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 4

ER -